ISC 2026 - Day 2

<h4>What if you could compress 179 days of grueling laboratory workflow into just 14 hours?</h4>In this episode of ‪ChromatographyTalk‬, ‪Organomation‬ General Manager David Oliva sits down with analytical chemist Laura Penabad to discuss her groundbreaking new research in biocatalysis and high-throughput screening. Evolving engineered enzymes typically requires checking thousands of variants—a massive bottleneck when traditional Liquid Chromatography-Mass Spectrometry (LC-MS) runs take minutes per sample. Laura reveals how her team built a modular screening platform that shatters this limitation, running samples 128 times faster than standard methods without sacrificing analytical accuracy.Laura breaks down the "orchestra" of technologies making this possible, including coupling nanoliter droplet microfluidics with Cyclic Ion Mobility-Mass Spectrometry (cIM-MS) to separate complex chemical isomers in milliseconds. She also shares the chaotic but triumphant behind-the-scenes stories of her PhD journey—from presenting a "comically bad" early poster at ASMS to recruiting an undergraduate mechanical engineer to build custom automation software from scratch.If you are an early-career researcher, a mass spec enthusiast, or curious about the future of synthetic biology and machine learning in chemistry, this episode is packed with invaluable intuition and advice.<h3>Video Transcription</h3><h4>From Months to Hours: Droplet Ion Mobility–MS for Biocatalysis Screening</h4>High-throughput screening is central to directed enzyme evolution, but conventional analytical workflows can create a difficult compromise: extremely fast screens often provide limited structural information, while techniques such as LC-MS offer much richer chemical insight at the cost of throughput. In a recent interview, analytical chemist Laura described how her work with droplet-based cyclic ion mobility mass spectrometry is helping bridge that gap—providing rapid analysis while retaining the ability to distinguish structurally similar products.Her research grew from an initially modest proof of concept into a screening platform capable of analyzing a 96-well plate in roughly ten minutes. The resulting workflow was approximately 128 times faster than a conventional three-minute LC-MS analysis, opening new possibilities for directed evolution campaigns in which thousands of enzyme variants need to be evaluated.<h4>Directed evolution needs better analytical screening</h4>Biocatalysis takes advantage of enzymes as highly selective catalysts capable of performing reactions under relatively mild conditions. Directed evolution extends those capabilities by deliberately modifying enzyme sequences, expressing large numbers of variants, screening their activity, and using the best-performing mutants as starting points for subsequent rounds of evolution.The process can be repeated multiple times, progressively steering an enzyme toward improved activity, altered substrate specificity, or even chemistry that does not occur naturally.But the effectiveness of directed evolution depends heavily on the screening step. The more variants that can be analyzed—and the more useful chemical information that can be collected for each one—the more effectively researchers can explore the enormous sequence space available to an enzyme.For Laura, this created a clear analytical challenge: develop a screening platform that was substantially faster than conventional chromatographic analysis without sacrificing the structural discrimination needed for chemically similar products.<h4>From an imperfect first experiment to a working platform</h4>The project did not begin with a polished high-throughput workflow.Laura recalled looking back at her 2023 ASMS poster, where the early system was still working with standards rather than true isomeric samples. Droplet introduction was slow—around six seconds per droplet—and the signals were far from the ideal reproducible, square, flat-topped profiles expected from replicate droplets.Nevertheless, simply producing a droplet signal represented an important first milestone.The decisive change came when the project stopped being treated merely as a demonstration that droplet ion mobility–MS could work and instead became a deliberate effort to build a robust screening platform.Laura approached the problem in modules. First came reliable droplet introduction. Then the ion mobility separation method. Quantification became another independent component. Matrix effects were introduced later, gradually making the system resemble the conditions expected with real screening samples.Each layer was tested before another was added.This stepwise strategy became one of the central principles of the project: rather than attempting to optimize the entire system simultaneously, individual components were developed, challenged, and then assembled into an increasingly realistic workflow.<h4>Finding the middle ground between speed and structural information</h4>One of the biggest analytical problems in high-throughput screening is distinguishing products with the same nominal or exact mass.Constitutional isomers may contain the same atoms and therefore generate the same mass-to-charge ratio, while differing only in how functional groups are arranged within the molecular structure. Very rapid optical or mass-based screens may therefore struggle to distinguish them.Traditional LC-MS can solve many of these problems through chromatographic separation, but a several-minute analysis rapidly becomes impractical when thousands of enzyme variants must be screened.Ion mobility offered Laura’s team another option.Rather than separating compounds on a chromatographic timescale, ion mobility can differentiate ions according to their gas-phase behavior on a much shorter timescale. In the workflow described in the interview, this created a useful compromise: not the kilohertz throughput possible with some simple screening technologies, but dramatically faster structural differentiation than conventional LC-MS.The goal was therefore not simply to achieve the fastest possible screen, but to find a middle-throughput analytical regime with enough resolving power to answer chemically meaningful questions.<h4>A 96-well plate in about ten minutes</h4>That strategy eventually produced one of the most striking results of the project.The droplet cyclic ion mobility–MS platform processed a 96-well plate in roughly ten minutes, while maintaining quantitative results comparable with the conventional LC-MS workflow used for comparison. According to the interview, this represented an approximately 128-fold increase in analysis speed relative to a three-minute LC-MS run.Laura described the successful plate experiment less as a surprise than as confirmation that the modular development strategy had worked.Before reaching that point, the workflow had already been challenged through a sequence of increasingly demanding experiments: droplet formation, ion mobility separation, calibration, matrix-containing calibration, and cross-testing analytes at different concentrations. By the time the complete plate was analyzed, each individual part of the analytical system had already been tested under progressively more realistic conditions.<h4>What does that speed mean for directed evolution?</h4>The impact becomes even clearer when the workflow is considered at the scale of an entire directed-evolution campaign.Laura’s manuscript estimated that a five-round campaign involving 5,000 variants would require approximately 179 days using the conventional LC-MS workflow but only about 14 hours using the new platform.Compressing months of analytical work into less than a day has consequences beyond laboratory productivity.It allows researchers to screen more enzyme variants and therefore sample a larger portion of sequence space. But the resulting datasets may also become increasingly valuable for computational approaches.Rather than retaining information only about the best-performing enzyme variant, researchers can preserve data describing variants that performed poorly as well as those that succeeded. When genotype and phenotype information remain linked through the well-plate workflow, these larger datasets can potentially provide richer input for machine-learning models designed to guide subsequent rounds of enzyme evolution.Faster analysis therefore does more than accelerate an existing experiment—it can change the scale and design of the experiment itself.<h4>Balancing ion mobility resolution and signal</h4>Increasing cyclic ion mobility separation time can improve resolution, but it also introduces an important trade-off: additional passes can reduce signal.Laura optimized this balance experimentally by continuously infusing mixtures containing both isomers and progressively adjusting the ion mobility conditions. After tuning parameters such as wave height and velocity, increasing the separation to three passes provided baseline resolution at the high analyte concentrations used during method development.<blockquote>Concentration, however, also mattered.</blockquote>At higher ion populations, space-charge effects could broaden peaks and reduce the baseline separation. This meant that the optimal number of passes could not be selected independently of the concentration range required by the final assay.Her broader advice for optimization is therefore application-driven: decide first what the analytical method actually needs to accomplish.More speed will almost always require sacrificing something—resolution, signal intensity, quantitative precision, or another performance parameter. The key is to identify which compromise the application can tolerate and then optimize the system around that requirement.<h4>Solving droplet carryover with a practical compromise</h4>Droplet-based workflows present their own engineering challenges, including carryover between neighboring samples.In Laura’s system, analytes showed little tendency to partition into the fluorinated oil separating aqueous droplets within the Teflon tubing. The more troublesome carryover occurred closer to electrospray ionization, where a small amount of sample could remain associated with the interface and appear when the next droplet arrived.Rather than adding excessive engineering complexity to an already elaborate platform, the researchers adopted a pragmatic solution: a sacrificial wash droplet between analytical samples.It is an example of a recurring theme throughout the project. The objective was not to construct the theoretically most sophisticated droplet system, but to create a screening workflow that remained sufficiently robust, reproducible, and practical for large numbers of samples.<h4>High-throughput analysis also requires high-throughput data processing</h4>Accelerating the mass spectrometry experiment created another bottleneck: the data.The instrument produced a continuous intensity-versus-time trace rather than a neatly organized well-plate dataset. With small experiments, Laura could manually identify individual droplets and process the results in spreadsheets. That approach quickly became unrealistic as sample numbers increased.The solution emerged through collaboration with an undergraduate mentee, Aiden, who helped develop a dedicated software tool for processing the continuous traces.Laura defined how the software should behave and how the analytical information should be organized, while Aiden developed the computational implementation. The workflow itself was subsequently adjusted to make automated data processing more reliable—for example, by introducing marker columns that allowed the software to recognize the end of each plate row.The resulting tool can accept the acquired traces together with information about plate dimensions and replicates and automatically return parameters including peak identity, duration, and the corresponding well position. A later version also generated an automatically populated heat map.The experience illustrates how improving analytical throughput often requires simultaneous development of instrumentation, experimental design, and informatics. Making the measurement faster is useful only if the resulting data can be processed at a comparable speed.<h4>Mentoring became part of the scientific process</h4>The software project also reflects another theme Laura emphasized throughout the interview: the value of mentoring.Several younger researchers contributed directly to the development of the final platform. Laura described mentees not simply as additional hands in the laboratory but as scientists capable of proposing their own hypotheses and experimental ideas.Working with undergraduate researchers also influenced the way she organized experiments.Because their available laboratory time was limited, each task needed to have a clear purpose. That encouraged a more disciplined approach to experimental planning: instead of performing experiments simply because they could be done, the team had to ask which experiment would most efficiently answer the next important question.In that sense, mentoring became another mechanism for improving the research itself.<h4>The next step: continuous, automated screening</h4>Despite the dramatic increase in analytical speed, the current workflow still includes manual operations such as loading tubing and connecting the sample stream to the mass spectrometer.The next engineering challenge is therefore automation.Laura described ongoing work using the Venturi effect to pull samples directly from wells into the droplet system. Building on previous work in the laboratory with 96-well plates, she has already tested this approach with as many as 2,000 samples.The long-term direction is clear: continuous and robust droplet generation, automated handling of thousands of samples, rapid ion mobility separation, mass spectrometric detection, and automated reconstruction of the resulting data into plate-based outputs.Combining those elements could move the system closer to the type of large-scale screening required for increasingly ambitious biocatalysis campaigns.<h4>Learning mass spectrometry one problem at a time</h4>Laura also reflected on the broader experience of developing the platform during her PhD.Ion mobility and mass spectrometry initially appeared intimidating, particularly because they combine concepts from analytical chemistry, physical chemistry, separations, instrumentation, and electrical engineering. What eventually changed was not simply learning more facts, but developing the ability to move repeatedly between theory and experiment.An unexpected result sends the researcher back to the underlying theory. A better understanding suggests a modified experiment. That experiment creates another observation, gradually building intuition about how the system behaves.Her advice to early-career scientists is therefore to accept that this process takes time.Advanced analytical techniques may initially appear overwhelming, but understanding develops incrementally through repeated interaction between theory, experimentation, failure, and refinement. Equally important, she emphasized the role of the supportive ion mobility–mass spectrometry community in making a technically demanding field more approachable for young researchers.From the first inconsistent droplets to a platform capable of processing thousands of samples, that iterative mindset ultimately shaped the entire project.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Droplet Cyclic Ion Mobility Mass Spec: Compressing Months of Enzyme Screening Into Just 14 Hours

ISC 2026 - Day 3

Article

Events

Video

Scientists

Interview

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Follistatin Analysis

Targeted HPLC analysis of follistatin in lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The Follistatin Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of follistatin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Follistatin is a protein rather than a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Follistatin</h4>Follistatin is a naturally occurring glycoprotein that binds activin with high affinity and regulates its biological activity. It also interacts with other members of the TGF-β superfamily and has been studied in connection with processes including muscle growth, reproduction, and tissue regulation.Follistatin occurs in several molecular forms and is widely used as a research target in studies of activin signalling and related biological pathways.<h4>Key Features</h4><ul><li>Targeted identification and quantification of follistatin</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Follistatin</li><li>Testing method: HPLC</li><li>Result format for lyophilisate: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for lyophilisate: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Follistatin is a protein rather than a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?search=Endotoxin">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

L-Carnitine analysis

Targeted HPLC analysis of L-carnitine in tablets, capsules, liquid samples, and raw API powders, confirming identity and determining content.

The L-Carnitine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of L-carnitine in oral dosage forms, liquid samples, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule, as well as liquid samples, with results reported in mg/ml. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About L-Carnitine</h4>L-carnitine is a naturally occurring compound involved in mitochondrial fatty-acid metabolism. Its primary biological role is to transport long-chain fatty acids across the inner mitochondrial membrane, enabling their subsequent beta-oxidation and use as a source of cellular energy.In the human body, L-carnitine is obtained from dietary sources and can also be synthesised endogenously from the amino acids lysine and methionine. It is concentrated particularly in tissues with high energy demands, such as skeletal and cardiac muscle, and is also used therapeutically in the management of primary and secondary carnitine deficiencies.<h4>Key Features</h4><ul><li>Targeted identification and quantification of L-carnitine</li><li>Suitable for tablets, capsules, liquid samples, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for liquid samples reported in mg/ml</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum liquid sample amount of 0.5–1 ml</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: L-Carnitine</li><li>CAS number: 541-15-1</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for liquid samples: mg/ml</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for liquid samples: 0.5–1 ml</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for L-carnitine. It does not automatically screen the sample for related carnitine derivatives, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>Purity reporting in % (m/m) is available as an alternative result format.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Lipo-C (L-Carnitine content, L-Arginine Content, B12 Content, Total Solids)

Lipo-C analysis determines L-carnitine, L-arginine, vitamin B12, and total solids content, with target compounds analysed by HPLC.

The Lipo-C Analysis is a targeted laboratory test designed to determine the content of L-carnitine, L-arginine, and vitamin B12, together with the total solids content of a Lipo-C sample.The target compounds are analysed by HPLC, with results reported in mg/ml. Total solids provide an additional measure of the overall amount of solid material present in the sample, helping assess the composition of the formulation beyond the individual quantified compounds.<h4>About the Analyzed Compounds</h4>L-carnitine is involved in mitochondrial fatty-acid metabolism and facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation. L-arginine is an amino acid involved in several metabolic pathways and serves as a precursor for nitric oxide synthesis.Vitamin B12 (cobalamin) is an essential micronutrient that functions as a cofactor for enzymes involved in important metabolic reactions and DNA synthesis.Total solids represent the overall solid material present in a sample, including dissolved and suspended material. This measurement complements the targeted determination of L-carnitine, L-arginine, and vitamin B12.<h4>Key Features</h4><ul><li>Targeted determination of L-carnitine, L-arginine, and vitamin B12</li><li>Total solids determination included</li><li>Analysis of target compounds by HPLC</li><li>Results reported in mg/ml</li><li>Suitable for Lipo-C liquid samples</li><li>Minimum sample amount of one whole unopened vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: L-Carnitine, L-Arginine, Vitamin B12</li><li>Additional determination: Total Solids</li><li>Testing method: HPLC</li><li>Result format: mg/ml</li><li>Minimum sample amount: One whole unopened vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically designed to determine L-carnitine, L-arginine, vitamin B12, and total solids in a Lipo-C sample.</li><li>The analysis does not automatically screen the sample for other active compounds, ingredients, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NAD+ analysis

Targeted HPLC analysis of NAD+ in tablets, capsules, and raw API powders, confirming compound identity and determining its amount.

The NAD+ Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of NAD+ in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). NAD+ is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About NAD+</h4>NAD+ (nicotinamide adenine dinucleotide) is the oxidized form of an essential cellular coenzyme involved in redox reactions and energy metabolism. It accepts electrons during metabolic reactions and is converted to its reduced form, NADH, which participates in cellular energy production.NAD+ is present throughout cellular metabolism and plays an important role in maintaining the balance between oxidation and reduction reactions required for normal cellular function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NAD+</li><li>Suitable for tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: NAD+</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: m/m purity in % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NAD+ is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NAD+. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>The stated detection limit cutoff is less than 1/20 of the usual dosage per vial.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NMN (Nikotinamid mononukleotid) analysis

Targeted HPLC analysis of NMN in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About NMN</h4>Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2546">NAD+</a>). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NMN</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Nicotinamide mononucleotide</li><li>Other name: NMN</li><li>CAS number: 1094-61-7</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sibutramine analysis

Targeted HPLC analysis of sibutramine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sibutramine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sibutramine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sibutramine</h4>Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that was formerly used as a weight-management medicine. By inhibiting the reuptake of serotonin and noradrenaline, it affects neurotransmitter signalling involved in appetite and satiety.Sibutramine-containing medicines were suspended in the European Union and withdrawn from the U.S. market after clinical data showed an increased risk of serious cardiovascular events, including heart attack and stroke.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sibutramine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sibutramine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 4 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sibutramine. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sibutramine required for evaluation is 4 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>Laboratory confirmation of sibutramine content should not be interpreted as confirmation that a product is safe for human use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SLU-PP-332 analysis

Targeted HPLC analysis of SLU-PP-332 in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About SLU-PP-332</h4>SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SLU-PP-332</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SLU-PP-332</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised vials: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.</li><li>DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.</li><li>This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T3 analysis

Targeted HPLC analysis of T3 (liothyronine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T3 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T3 (liothyronine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T3</h4>T3, or triiodothyronine, is a naturally occurring thyroid hormone involved in the regulation of metabolism, growth, and energy utilisation. Liothyronine is the synthetic form of T3 used in pharmaceutical preparations.Liothyronine sodium is used clinically as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism. Cytomel is one of the established trade names for liothyronine sodium.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T3</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T3</li><li>Other names: Cytomel, Tiromel, liothyronine sodium</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T3. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T3 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T4 analysis

Targeted HPLC analysis of T4 (thyroxine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T4 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T4 (thyroxine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T4</h4>T4, or thyroxine, is the major thyroid hormone produced and secreted by the thyroid gland. It plays an important role in the regulation of metabolism, growth, development, and energy utilisation. Much of circulating T4 is converted in peripheral tissues to the more biologically active thyroid hormone <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2550">T3</a>.Levothyroxine is the synthetic form of T4 and is widely used as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T4</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T4</li><li>Other name: Thyroxine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T4. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T4 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tesofensine analysis

Targeted HPLC analysis of tesofensine in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The Tesofensine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tesofensine in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised samples, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Tesofensine is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Tesofensine</h4>Tesofensine is a centrally acting monoamine reuptake inhibitor that inhibits the reuptake of serotonin, noradrenaline, and dopamine. Its effects on these neurotransmitter systems have been investigated primarily in relation to appetite regulation and body weight.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tesofensine</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tesofensine</li><li>CAS number: 195875-84-4</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised samples: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Tesofensine is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for tesofensine. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For raw API powders, at least 30 mg should be supplied in a sealed glass vial to minimise moisture absorption.</li><li>Purity reporting in % (m/m) is available for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on Laboratory analysis - page 6

Related content

ISC 2026 - Day 3

Droplet Cyclic Ion Mobility Mass Spec: Compressing Months of Enzyme Screening Into Just 14 Hours

ISC 2026 - Day 2